<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Lung cancer in never smokers
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Lung cancer in never smokers
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Lung cancer in never smokers
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Heather Wakelee, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rogerio C Lilenbaum, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 24, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lung cancer is the leading cause of cancer death worldwide, causing about 1.8 million deaths per year [
         <a href="#rid1">
          1,2
         </a>
         ]. Exposure to tobacco smoke is the primary etiologic factor responsible for lung cancer, and its importance is illustrated by the decline in lung cancer incidence and mortality in the United States that has accompanied the decline in smoking [
         <a href="#rid3">
          3-5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4640.html" rel="external">
          "Cigarette smoking and other possible risk factors for lung cancer"
         </a>
         .)
        </p>
        <p>
         Despite the predominance of tobacco smoking as its presumed etiology, lung cancer is also a significant health problem in those with no history of smoking [
         <a href="#rid6">
          6,7
         </a>
         ]. Lung cancer in people who have never smoked is distinct enough from an epidemiologic and biologic standpoint to be considered a separate entity [
         <a href="#rid8">
          8-11
         </a>
         ]. Furthermore, as the number of people who have never smoked in the United States and other countries rise, the issue of lung cancer in this group is a growing public health concern.
        </p>
        <p>
         The epidemiology, risk factors, biologic differences, and potential implications for treatment of lung cancer in people who have never smoked are reviewed here. General aspects of lung cancer biology and management are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4641.html" rel="external">
          "Clinical manifestations of lung cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4639.html" rel="external">
          "Overview of the initial treatment and prognosis of lung cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4607.html" rel="external">
          "Overview of the initial treatment of advanced non-small cell lung cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, the term "never smoker" refers to individuals who have smoked fewer than 100 cigarettes in their lifetime. The incidence of small cell lung cancer in never smokers is exceedingly small [
         <a href="#rid12">
          12
         </a>
         ], and this discussion will therefore focus on non-small cell lung cancer (NSCLC), predominantly adenocarcinoma (while 50 to 60 percent of cancers in never smokers are adenocarcinomas, only approximately 10 to 20 percent are squamous cell carcinomas [
         <a href="#rid13">
          13
         </a>
         ]).
        </p>
        <p>
         Firm data on the incidence of lung cancer in never smokers is difficult to ascertain because most population-based cancer registries, including the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database, do not collect patient smoking information. SEER data have been linked with population-based tobacco use information [
         <a href="#rid14">
          14
         </a>
         ], but this only allows for estimates of lung cancer in never smokers within broad geographic areas.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Incidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Worldwide, smoking accounts for approximately two-thirds of lung cancer cases, with the remaining occurring due to other causes [
         <a href="#rid1">
          1
         </a>
         ]. There are major geographic and gender differences, particularly in Asia, where 60 to 80 percent of women with the disease have never smoked [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         In one analysis in the United States, an estimated 19 percent of women with lung cancer had never smoked, compared with approximately 9 percent of men with the disease [
         <a href="#rid15">
          15
         </a>
         ]. These results are based upon an analysis of data from patients in five large United States cohort studies [
         <a href="#rid16">
          16-21
         </a>
         ]. The age-adjusted incidence rate for lung cancer in never smokers aged 40 to 79 years ranged from 11.2 to 13.7 per 100,000 person-years for males and from 15.2 to 20.8 per 100,000 person-years for females. These incidence rates are similar to those for myeloma in men or cervical cancer in women in this country [
         <a href="#rid22">
          22
         </a>
         ]. By contrast, the age-adjusted rates of lung cancer in current smokers in the same cohorts were approximately 12 to 30 times higher.
        </p>
        <p>
         An analysis of lung cancer patients diagnosed between 1991 and 2005 in Southern California utilized a novel text-mining programming algorithm to evaluate smoking status based on information from electronic medical record abstracts in the regional cancer registry. This study determined that 8.9 percent of over 25,000 patients with known smoking status were never smokers, including 6 percent of males and 14 percent of females [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p>
         Another analysis of 13 cohorts and 22 cancer registries, however, did not find any apparent difference in the incidence rate of lung cancer in people who had never smoked by sex overall, although females had a higher incidence rate than males among never smokers aged 40 to 59 years [
         <a href="#rid25">
          25
         </a>
         ]. In this multinational analysis, the age-standardized incidence rates for lung cancer (per 100,000 using the 2000 world population age standard) for females were 12.4 for women of European descent, 15 for Asian women, and 19.4 for African American women. This compared with rates of 11.2, 12.9, and 12.3, respectively, for men of European, Asian, and African American background.
        </p>
        <p>
         Whether the incidence of lung cancer in never smokers has been changing over time had been debated, with older studies yielding conflicting results:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study from the Swedish construction worker's health care program, which is linked to the national cancer registry, showed a substantial increase in the age-adjusted incidence rate of nonsmoking lung cancer comparing the period 1976 to 1980 with 1991 to 1995 (1.5 versus 5.4 per 100,000) [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two American Cancer Society prevention study cohorts found a statistically significant but smaller increase in the mortality rate in women due to nonsmoking-associated lung cancer comparing the period 1959 to 1972 with 1982 to 2000 (12.3 to 14.7 per 100,000) in 1982 to 2000 [
         <a href="#rid27">
          27
         </a>
         ]. The rates did not change over time for men.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Indirect evidence comes from a series of nearly 12,000 patients with lung cancer in Southern California [
         <a href="#rid28">
          28
         </a>
         ]. Comparing the interval 1995 to 1999 with 1999 to 2003, the percentage of never smokers with the subtype formerly known as bronchioloalveolar carcinoma increased from 19 to 26 percent, while the percentage with other forms of lung cancer went from 8.6 to 9.4 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Data collected from cancer registries in Japan and Southern California with smoking information focused on lung cancer in never smokers over two time periods, 1991 to 1996 and 1997 to 2001, and did not show a substantial numerical change in the percent of lung cancer patients who were never smokers during the two time periods (28 and 31 percent versus 7.2 and 7.4 percent for the Japanese and Southern Californian registries at earlier and later time periods, respectively) [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a previous comparison of two case-control studies from the United Kingdom done at the same hospitals and community settings in 1950 and in 1990, the percentage of never smokers among male lung cancer cases did not change, although the percentage of never smokers among the controls increased from 4.5 to 19 percent [
         <a href="#rid30">
          30
         </a>
         ]. The percentage of lung cancer in never smokers who were women dropped dramatically during this time period, while the rate of smoking in the controls dropped less dramatically. A subsequent analysis of early-stage lung cancer cases from a single institution in the United Kingdom, though, demonstrated an increase in the annual frequency of lung cancer in never smokers from 13 to 28 percent looking from 2008 to 2014 [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A single institution evaluation from Japan found that over the 30-year period 1974 to 2004, the proportion of never smoking, early-stage NSCLC patients increased from approximately 16 to 33 percent [
         <a href="#rid8">
          8
         </a>
         ]. The large pooled analysis of 13 cohorts compared contemporary rates with those in Connecticut in the 1930s when smoking was very rare in women and found no substantial change over time [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         A pooled analysis of over 10,000 patients treated from 1990 to 2013 at three large academic hospitals in the southern United States identified an increase in the proportion of people who had never smoked with lung cancer from 8 percent in 1990 to 1995 to 14.9 percent in 2011 to 2013 (p &lt;0.001) in a multivariable logistic regression analysis that accounted for sex, stage, and ethnicity [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         A similar analysis looking at the proportion of newly diagnosed patients who were never smokers at a large institution in Singapore in 1999 to 2002 versus 2008 to 2011 found the proportion of lung cancer patients who were never smokers increased from 31 to 48 percent (p &lt;0.001) [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Cancer registry data will need to collect information on the smoking status of patients in order to carefully examine trends in the incidence rate of lung cancer among never smokers. Self-reported smoking status can be challenging to obtain, but the validity of this method has been verified in several studies that have shown only small smoker misclassification rates [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p>
         Though the data are unclear, the increasing prevalence of lung cancer in patients without a smoking history is widely accepted. In Taiwan for example, 55 percent of the lung cancers develop in people who have never smoked, with 90 percent of women who develop lung cancer having no history of smoking. These observations have led to lung cancer screening programs in patients without a smoking history (TALENT trial) [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Sex
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite the fact that a higher percentage of women with lung cancer have never smoked compared with men as reported in several analyses [
         <a href="#rid6">
          6,15,37,38
         </a>
         ], the age-adjusted mortality rate from lung cancer among never smokers was higher in men than women in two American Cancer Society cancer prevention study cohorts [
         <a href="#rid27">
          27
         </a>
         ]. These two cohorts formed the bulk of patients of European ancestry in a larger pooled analysis of 13 cohort studies and multiple cancer registries that showed age-standardized lung cancer mortality rates of 12 per 100,000 for never smoking men and 9.5 per 100,000 for never smoking women of European ancestry. In Asian populations, the rates were 26 and 16.1 per 100,000 for men and women, respectively [
         <a href="#rid25">
          25
         </a>
         ]. Women with lung cancer live longer than men, but how much this explains the differences seen between incidence and mortality is not known [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1431.html" rel="external">
          "Females and lung cancer", section on 'Outcome'
         </a>
         .)
        </p>
        <p>
         By contrast, in a Japanese study, 33 percent of lung cancer deaths in men and 85 percent of lung cancer deaths in women were not due to cigarette smoking. In Japan, the percentage of women with lung cancer who are never smokers is much higher [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Ethnicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of smoking-associated lung cancer differs by race/ethnicity. Accurate data on differences in rates of lung cancer among never smokers based upon race or ethnicity are extremely limited.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A Southern California analysis of over 20,000 patients found that for women, 46 percent of all lung cancer in Asian/Pacific Islanders occurred in never smokers compared with 25 percent in Hispanic individuals, 11 percent in African Americans, and 10 percent in non-Hispanic White individuals [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A Northern California analysis of lung cancer cases diagnosed from 1998 to 2008 found that for women, of all lung cancer cases identified, 71 percent of lung cancer in Asian/Pacific Islanders occurred in never smokers compared with 35 percent of cases in Hispanic women and 40 percent in non-Hispanic White individuals [
         <a href="#rid42">
          42
         </a>
         ]. This study also looked at survival differences in these groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Further data on this topic come from a large pooled analysis of cohort and registry data that show wide variability in incidence and mortality from lung cancer in never smokers, even within certain Asian countries including China and Thailand, but overall increased rates in African Americans compared with other ethnic groups [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Age
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although it has been postulated that lung cancer occurs at a younger age in never smokers [
         <a href="#rid43">
          43
         </a>
         ], this has only been validated in some [
         <a href="#rid38">
          38
         </a>
         ], but not all, cohort analyses in Western populations [
         <a href="#rid15">
          15
         </a>
         ]. In studies from Asia, however, a younger age at diagnosis is characteristic of lung cancer people who have never smoked [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The known and potential causes of lung cancer are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4640.html" rel="external">
          "Cigarette smoking and other possible risk factors for lung cancer"
         </a>
         .)
        </p>
        <p>
         The causative factors for lung cancer in never smokers are not well understood. The risk factors that are considered to be most important among never smokers are discussed here.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Secondhand smoke
         </span>
         <span class="headingEndMark">
          —
         </span>
         Secondhand smoke is an important risk factor for lung cancer among never smokers [
         <a href="#rid34">
          34,45-47
         </a>
         ]. However, the extent of this problem is not clear. (See
         <a class="medical medical_review" href="/z/d/html/6919.html" rel="external">
          "Secondhand smoke exposure: Effects in adults", section on 'Lung cancer'
         </a>
         .)
        </p>
        <p>
         Several studies suggest that approximately 15 to 35 percent of lung cancer among never smokers is due to secondhand smoke [
         <a href="#rid48">
          48-52
         </a>
         ] and that risk may be increased in those with exposure prior to age 25 [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study from France of 1493 lung cancer patients found that 79 percent of women and 21 percent of men who were never smokers had secondhand smoke exposure [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A population-based case-control study in Canada of 445 cases and 948 controls found no association between exposure to secondhand smoke at home or the workplace and development of lung cancer [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A population-based prospective study in Japan reported a hazard ratio (HR) of 2.03 (95% CI 1.07-3.86) for development of adenocarcinoma for never smoking women who lived with a smoking husband as compared with never smoking women with a nonsmoking spouse [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A United States case-control study reported an increase in lung cancer risk in never smokers with secondhand smoke exposure during childhood (odds ratio [OR] 2.5; 95% CI 1.04-4.90) [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a report based upon the largest sample, analysis from a case-control study in Europe of 520,000 people estimated that the proportion of lung cancer related to secondhand smoke was 16 to 24 percent in nonsmokers [
         <a href="#rid51">
          51
         </a>
         ]. An additional 5 to 7 percent of lung cancer among never smokers was thought to be due to air pollution.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Spousal smoking increased the risk of lung cancer in a never smoking spouse (relative risk [RR] 1.27, 95% CI 1.17-1.37) in a meta-analysis that included 55 international studies [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the European Prospective Investigation into Cancer and Nutrition study evaluating the risk of cancer in nearly 500,000 people, the risk of lung cancer in never smokers was significantly elevated in those with secondhand smoke exposure (HR 1.65, 95% CI 1.04-2.63) [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Subsequent data demonstrate the challenges in proving secondhand smoke as a truly causative factor in the development of lung cancer in never smokers.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Women's Health Initiative (WHI) observational study included over 76,000 women with a complete smoking history [
         <a href="#rid58">
          58
         </a>
         ]. With a mean follow-up of 10.5 years, 901 cases of lung cancer were identified. Among the never smokers, there was no overall association with passive smoking exposure (HR 0.88, 95% CI 0.52-1.49), although there was a trend toward an increase in women never smokers with adult-home passive smoking exposure (HR 1.61, 95% CI 1.00-2.58).
        </p>
        <p>
        </p>
        <p>
         The hypothesis that secondhand smoke may be responsible for higher rates of lung cancer in never smokers in Asia was questioned by whole-genome sequencing of lung cancer from Asian patients with and without a smoking history. The mutational signatures of the Asian never-smoker lung cancers were very similar to those of European never-smoker lung cancers but different from the patterns of smokers in either group [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Radon
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radon is a gaseous decay product of uranium-238 and radium-226, which is capable of damaging respiratory epithelium via the emission of alpha particles. The increased risk of lung cancer among uranium miners has been more clearly established and is thought to be due to radiation from radon [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4640.html" rel="external">
          "Cigarette smoking and other possible risk factors for lung cancer", section on 'Radon'
         </a>
         .)
        </p>
        <p>
         Radon is present in soil, rock, and groundwater, and it can accumulate in homes. Exposure to radon within the home may play a role in the development of lung cancer in never smokers [
         <a href="#rid61">
          61-63
         </a>
         ], although this is controversial [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Environmental exposures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other occupational exposures are known to increase lung cancer risk in smokers, and to a lesser extent, in never smokers as well.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Commonly associated toxins include asbestos, chromium, and arsenic [
         <a href="#rid65">
          65-68
         </a>
         ]. Occupational exposure to organic dust has been linked as a risk factor for lung cancer [
         <a href="#rid69">
          69
         </a>
         ]. A Dutch analysis of occupational asbestos exposure found an RR of lung cancer of 3.5 after controlling for age, smoking, and other factors [
         <a href="#rid68">
          68
         </a>
         ]. In a French study of 1493 cases, some occupational exposure was identified in 9.4 percent of women and 48.6 percent of men who developed lung cancer as never smokers [
         <a href="#rid52">
          52
         </a>
         ]. In a Canadian case-control study, the OR for lung cancer risk from occupational exposures in never smokers was 2.1 (95% CI 1.3-3.3) but was higher for exposure to solvents, paints, or thinners (OR 2.8, 95% CI 1.6-5.0) [
         <a href="#rid38">
          38
         </a>
         ]. A meta-analysis focused on lung cancer risk in painters reported an RR for lung cancer in all painters of 1.35 (95% CI 1.29-1.41) but 2.0 (95% CI 1.09-3.67) in the never smokers [
         <a href="#rid70">
          70
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4307.html" rel="external">
          "Asbestos-related pleuropulmonary disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arsenic has implicated as a cause of lung cancer where it contaminates drinking water, such as in some areas of Taiwan and Chile [
         <a href="#rid71">
          71,72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Various dietary factors have been studied as possible causes of lung cancer but none are clearly implicated. Higher intake of fruits and vegetables may be protective against lung cancer [
         <a href="#rid40">
          40,73,74
         </a>
         ]. A case-control study from Italy found an RR for lung cancer of 2.4 (95% CI 1.4-4.0) for the highest versus lowest quartiles of red meat consumption in never smokers [
         <a href="#rid75">
          75
         </a>
         ], and another report indicated that higher consumption of fish may protect against lung cancer in never smokers [
         <a href="#rid76">
          76
         </a>
         ]. A separate United States study focused exclusively on never smokers reported a reduced risk of lung cancer in those with the "healthiest" dietary patterns (ie, high consumption of fruits and vegetables and of low-fat foods) [
         <a href="#rid77">
          77
         </a>
         ]. In one pooled analysis of 22 case-control and cohort studies including over 2500 never smoking lung cancer patients and over 9000 never smoking controls, the consumption of low-moderate amounts of alcohol was potentially protective against lung cancer [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Indoor air pollutants such as vapors from cooking oil and the smoke from burning coal have been linked to lung cancer, particularly in Asia [
         <a href="#rid79">
          79-82
         </a>
         ], although there is some controversy about the importance of this [
         <a href="#rid83">
          83-85
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Outdoor air pollution is also associated with lung cancer risk. Using mean long-term ambient fine particulate matter (PM2.5) as a measure of air pollution, there was a 15 to 27 percent increase in lung cancer mortality in never smokers for each 10 mcg/m
         <sup>
          3
         </sup>
         increase in PM2.5 concentrations in the Cancer Prevention Study-II [
         <a href="#rid86">
          86
         </a>
         ]. A meta-analysis including this and 17 other studies concluded that the meta-RR for lung cancer associated with PM2.5 was 1.09 (95% CI 1.04-1.14); this was particularly evident in never smokers (meta-analysis RR 1.18, 95% CI 1.00-1.39) [
         <a href="#rid87">
          87
         </a>
         ]. A link between air pollution and lung cancer has been described. Increasing PM2.5 levels have been associated with increased rates of epidermal growth factor receptor (
         <em>
          EGFR
         </em>
         ) mutated lung cancer, amongst other malignancies [
         <a href="#rid88">
          88
         </a>
         ].
         <em>
          EGFR
         </em>
         mutated non-small cell lung cancer (NSCLC) is exceedingly common in never smokers who develop lung cancer and very rare in those who develop lung cancer with a smoking history. PM has been shown to promote inflammation (partly through the IL1B pathway) that allows lung cells with driver mutations to fully develop into malignancy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Lung disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of lung cancer among never smokers is increased in those with prior damage to the lungs from underlying pulmonary disease or exposure to radiation or chemotherapy [
         <a href="#rid38">
          38,89-92
         </a>
         ]. The magnitude of this risk is unclear because the vast majority of pulmonary disease is related to smoking. When one looks at idiopathic pulmonary fibrosis, the literature is conflicting regarding the association with lung cancer, though an association does seem to be supported by the majority of studies [
         <a href="#rid93">
          93,94
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4640.html" rel="external">
          "Cigarette smoking and other possible risk factors for lung cancer", section on 'Inflammation and benign lung disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H551742669">
         <span class="h2">
          Oncogenic viruses
         </span>
         <span class="headingEndMark">
          —
         </span>
         A viral etiology for some lung cancer is under investigation, with a particular focus on the role of human papillomavirus (HPV) [
         <a href="#rid95">
          95,96
         </a>
         ].
        </p>
        <p>
         In a case-control study of 141 lung cancer patients and 60 noncancer controls from Taiwan, HPV serotypes 16 and 18 were significantly more common among those with lung cancer (55 versus 27 percent) [
         <a href="#rid97">
          97
         </a>
         ]. This association was most prominent among older nonsmoking women. However, this high incidence of HPV positivity was not observed in a series of patients [
         <a href="#rid98">
          98
         </a>
         ], and a subsequent meta-analysis of the literature was inconclusive about the potential role of HPV in the etiology of lung cancer in never smokers [
         <a href="#rid99">
          99
         </a>
         ]. Detailed pathologic evaluation and HPV genotyping of 334 lung tumors identified HPV DNA in 10 percent, but viral oncogenes were not identified, thus failing to support a causal association [
         <a href="#rid100">
          100
         </a>
         ]. In a detailed analysis of early-stage lung cancer in Japan, only 0.3 percent of patients were found to be HPV positive [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Genetic factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple studies have shown an association between lung cancer in never smokers and a family history of lung cancer, suggesting a role for genetic factors [
         <a href="#rid38">
          38,46,102-106
         </a>
         ].
        </p>
        <p>
         As an example, in a case-control study of 257 cases of lung cancer among never smokers and an equivalent number of control never smokers, lung cancer was significantly more common among those with a positive family history (OR 7.2) [
         <a href="#rid105">
          105
         </a>
         ]. In another case-control study that included over 2400 relatives of 316 never smoker lung cancer cases, there was a 25 percent excess risk of any type of cancer among first-degree relatives of cases, particularly of early-onset lung cancer (&lt;50 years) among those relatives who smoked [
         <a href="#rid106">
          106
         </a>
         ]. In an analysis from the Environment And Genetics in Lung cancer Etiology study, the RR of lung cancer associated with a positive family history, adjusted for age, gender, residence, education, and smoking, was 1.57 (95% CI 1.25-1.98) [
         <a href="#rid107">
          107
         </a>
         ]. Efforts to decipher the interactions between family history and environment exposure in the development of lung cancer in never smokers will be aided by an environmental exposure index developed to look at these questions in Chinese never smokers. There was an OR of 30.6 (95% CI 9.4-99.9) for men with both positive family history and high environmental exposure compared with those with neither, but the associations in women were not as strong with this model [
         <a href="#rid108">
          108
         </a>
         ]. Suboptimal DNA repair capacity as measured by the host-cell reactivation assay nearly doubled the risk of lung cancer in a case-control study of never smokers (RR 1.92, 95% CI 1.3-2.9) [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
         Studies have suggested susceptibility loci for lung cancer in never smokers at various locations including chromosomes 6q [
         <a href="#rid110">
          110
         </a>
         ], 5p15.33 (
         <em>
          TERT
         </em>
         ) [
         <a href="#rid111">
          111-113
         </a>
         ], 13q31.3 (
         <em>
          GPC5
         </em>
         ) [
         <a href="#rid114">
          114
         </a>
         ], 15q25, and 6p21 [
         <a href="#rid115">
          115
         </a>
         ], and in a Korean population at 18p11.22 [
         <a href="#rid116">
          116
         </a>
         ]. However, the results of genome-wide association studies (GWAS) have not been consistent [
         <a href="#rid117">
          117
         </a>
         ]. Pooled data from 14 studies of ethnic Chinese patients (n = 5510 never smoking women with lung cancer and 4544 controls) reported three new susceptibility loci (10q25.2, 6q22.2, and 6p21.32) and confirmed the 5p15.33, 3q28, and 17q24.3 loci [
         <a href="#rid118">
          118
         </a>
         ]. However, the studies in this analysis included some of the trials used initially to identify certain loci.
        </p>
        <p>
         A large GWAS in never smokers from two large United States academic centers and a confirmation cohort from Taiwan identified two potential loci associated with decreased survival in never smokers, but these were different from loci identified by other groups, which might be related to lung cancer susceptibility [
         <a href="#rid119">
          119
         </a>
         ]. In Korea, an analysis of 181 never smoking women with lung cancer and 179 controls identified colony-stimulating factor 1 receptor (
         <em>
          CSF1R
         </em>
         ) as a candidate gene of interest for lung cancer susceptibility in this group [
         <a href="#rid120">
          120
         </a>
         ].
        </p>
        <p>
         Specific germline mutations have been identified in limited numbers of families with high rates of NSCLC in never smokers. The best understood are germline mutations in the
         <em>
          EGFR
         </em>
         [
         <a href="#rid121">
          121-124
         </a>
         ]. Few other germline mutations have been reported in association with increased lung cancer risk in never smokers, but a novel germline mutation in human epidermal growth factor 2 (
         <em>
          HER2
         </em>
         ) was identified in a Japanese family with nine affected family members [
         <a href="#rid125">
          125
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Estrogens
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of estrogens and other female hormones in lung cancer risk in women is uncertain, regardless of smoking status. Multiple studies have shown that the majority of NSCLCs express the estrogen receptor beta [
         <a href="#rid126">
          126-128
         </a>
         ] and that the expression of this receptor is more common in never smokers compared with smokers [
         <a href="#rid129">
          129
         </a>
         ].
        </p>
        <p>
         The clinical implications of these laboratory studies are unclear. Multiple studies have looked at the relationship of lung cancer incidence to early menopause [
         <a href="#rid130">
          130,131
         </a>
         ], use of hormone therapy [
         <a href="#rid132">
          132,133
         </a>
         ], age at first birth [
         <a href="#rid134">
          134
         </a>
         ], number of children [
         <a href="#rid135">
          135
         </a>
         ], and use of
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         [
         <a href="#rid136">
          136
         </a>
         ]. However, the results have been inconsistent in establishing a relationship. Data from the randomized WHI trial indicated that women assigned to postmenopausal estrogen and
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         had a higher risk of death from lung cancer without a higher incidence of the disease compared with women assigned to placebo [
         <a href="#rid137">
          137
         </a>
         ]. However, women randomized to estrogen alone had no such increase in lung cancer mortality, nor in lung cancer incidence, compared with those on placebo [
         <a href="#rid138">
          138
         </a>
         ]. Further analyses of the WHI trial indicated that the incidence and mortality of lung cancer did not differ by hormone use in never smoking women, but mortality from lung cancer was significantly higher in smoking women who used estrogen plus progesterone hormone therapy compared with smoking women who did not [
         <a href="#rid139">
          139
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          BIOLOGIC DIFFERENCES COMPARED WITH LUNG CANCER IN PEOPLE WHO HAVE SMOKED
         </span>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Pathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adenocarcinoma is more common in never smokers, light smokers, and former smokers while squamous cell carcinoma and small cell lung cancer are seen with a higher incidence in heavy smokers [
         <a href="#rid6">
          6,7
         </a>
         ]. In a review of published reports on the histology of lung cancer that included smoking data, adenocarcinoma was more common than squamous cell carcinoma among nonsmokers (62 versus 18 percent, based upon 5144 cases). By contrast, adenocarcinoma was less frequent among smokers (19 versus 53 percent in 21,853 cases) [
         <a href="#rid6">
          6
         </a>
         ]. Subsequent series of lung cancer in never smokers continue to report adenocarcinoma as the most common histology [
         <a href="#rid15">
          15,41,44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Molecular biology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contemporary advances in the understanding of the molecular biology of lung cancer have led to the identification of substantial differences between never smokers compared with smokers with lung cancer. These factors are arguably more important than any clinical differences. (See
         <a class="medical medical_review" href="/z/d/html/16538.html" rel="external">
          "Personalized, genotype-directed therapy for advanced non-small cell lung cancer"
         </a>
         .)
        </p>
        <p>
         In one study performing whole-exome and RNA sequencing in patients with lung adenocarcinoma, there was a higher prevalence of clinically actionable driver alterations in never smokers compared with smokers (78 to 92 percent versus 50 percent) [
         <a href="#rid140">
          140
         </a>
         ].
        </p>
        <p>
         One of the most apparent differences between lung cancer in never smokers versus current and former smokers is in the expression and mutations of the epidermal growth factor receptor (
         <em>
          EGFR
         </em>
         ). Mutations in the
         <em>
          EGFR
         </em>
         gene are more common in lung tumors from people who have never smoked compared with those with a smoking history [
         <a href="#rid141">
          141-146
         </a>
         ]. Several analyses of patients with the most common activating mutations in the
         <em>
          EGFR
         </em>
         gene (predominantly deletions in exon 19 and the L858R mutation on exon 21) report that the frequency of the mutations, especially exon 19 and 21 mutations, is much higher in never smokers than ever smokers (p &lt;0.001) in both men and women [
         <a href="#rid147">
          147,148
         </a>
         ]. In addition, a distinct immunohistochemical profile of the EGFR pathway has also been identified in never versus current smokers, even in the absence of
         <em>
          EGFR
         </em>
         mutations [
         <a href="#rid149">
          149
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4630.html" rel="external">
          "Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor"
         </a>
         .)
        </p>
        <p>
         The contribution of secondhand exposure to tobacco smoke to the incidence of
         <em>
          EGFR
         </em>
         mutations in never smokers is unclear. In a Korean study of 179 never smokers with non-small cell lung cancer (NSCLC),
         <em>
          EGFR
         </em>
         mutations were significantly less frequent in those with a positive history of secondhand tobacco smoke (39 versus 61 percent), and there was a progressive decrease in the incidence with increasing secondhand tobacco smoke exposure [
         <a href="#rid150">
          150
         </a>
         ]. This is in contrast to a Japanese publication focused on 126 never smokers with NSCLC, which reported an increase in
         <em>
          EGFR
         </em>
         -activating mutations with increasing secondhand smoke exposure [
         <a href="#rid151">
          151
         </a>
         ]. (See
         <a class="local">
          'Secondhand smoke'
         </a>
         above.)
        </p>
        <p>
         Kirsten rat sarcoma viral oncogene homolog
         <em>
         </em>
         (
         <em>
          KRAS
         </em>
         ) mutations have been thought to be more common in lung cancer patients who are ever smokers [
         <a href="#rid146">
          146,152
         </a>
         ]. An analysis of 482 lung adenocarcinomas, however, found that the rate of
         <em>
          KRAS
         </em>
         mutations in codons 12 and 13 was not significantly different in never smokers (15 percent) compared with former smokers (22 percent) and current smokers (25 percent) [
         <a href="#rid153">
          153
         </a>
         ]. The nature of the mutations was significantly different though, with more transition mutations (G to A) compared with transversion mutations (G to T or G to C) in tumors from patients with a smoking history.
        </p>
        <p>
         A fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (
         <em>
          EML4
         </em>
         ) gene and the anaplastic lymphoma kinase (
         <em>
          ALK
         </em>
         ) gene in NSCLC is found in 3 to 7 percent of NSCLC and appears to be nearly mutually exclusive with
         <em>
          EGFR
         </em>
         and
         <em>
          KRAS
         </em>
         mutations [
         <a href="#rid154">
          154
         </a>
         ]. This frequency is higher in those who develop lung cancer as never smokers [
         <a href="#rid154">
          154-156
         </a>
         ]. The rate of
         <em>
          ALK
         </em>
         fusion oncogene positivity was nearly 20 percent of NSCLC in one study from China and 42 percent in those patients in that analysis who were known to have wildtype
         <em>
          EGFR
         </em>
         and
         <em>
          KRAS
         </em>
         [
         <a href="#rid157">
          157
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4621.html" rel="external">
          "Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer"
         </a>
         .)
        </p>
        <p>
         Differences have also been observed in the expression patterns and mutations for other genes when never smokers are compared with smokers. Examples of these include p53 [
         <a href="#rid152">
          152,158
         </a>
         ], the nucleotide excision repair family of proteins, including ERCC1, involved in DNA repair [
         <a href="#rid159">
          159
         </a>
         ], p38 (downstream of mitogen-activated protein kinase [MAPK]) [
         <a href="#rid160">
          160
         </a>
         ], ataxia telangiectasia mutated (ATM) [
         <a href="#rid161">
          161
         </a>
         ], nitrotyrosine (a marker of nitric oxide protein damage) [
         <a href="#rid152">
          152
         </a>
         ], other chromosomal abnormalities [
         <a href="#rid162">
          162,163
         </a>
         ], and methylation of p16 [
         <a href="#rid164">
          164,165
         </a>
         ]. The microRNA-21 (miR-21) appears to be increased in lung cancer in never smokers, particularly in those with
         <em>
          EGFR
         </em>
         mutations and may play a significant role in lung carcinogenesis [
         <a href="#rid166">
          166
         </a>
         ]. Additionally, mitochondrial DNA mutations in the respiratory complex-I have been reported to differ between never smokers and smokers with lung cancer [
         <a href="#rid167">
          167
         </a>
         ].
        </p>
        <p>
         The results of whole-genome and transcriptome sequencing of tumor (adenocarcinoma in 16 and large cell in 1) and adjacent tissue from 17 early-stage NSCLC patients identified average mutation frequency to be significantly higher in NSCLC patients with a smoking history compared with never smokers (n = 5 plus 1 light smoker) [
         <a href="#rid168">
          168
         </a>
         ]
         <em>
          .
         </em>
         The number of mutations per megabase (Mb) in the cancers of the smokers (median 10.5) was significantly higher compared with the cancers in the never smokers (median 0.6 mutations per Mb) and the single former light smoker (0.3 mutations per Mb). The work also confirmed presence of
         <em>
          EGFR
         </em>
         and
         <em>
          KRAS
         </em>
         mutation in founder clones, supporting the hypotheses that these are true "driver" mutations when identified, and found novel gene changes in DNA repair and cell cycle pathways. The tumors from both smokers and never smokers were heterogeneous with multiple subclones. In another study of six Korean women never smokers, high-throughput multidimensional sequencing of lung adenocarcinoma tumor and adjacent normal tissue found multiple gene mutations, but only one patient had a recognized "driver" mutation, CCDC6-RET fusion [
         <a href="#rid169">
          169
         </a>
         ].
        </p>
        <p>
         Focused efforts to determine frequencies of the known "driver" mutations in NSCLC (ie, those mutations that appear to be the driving force in a cancer) are ongoing in multiple collaborations. The National Cancer Institute's Lung Cancer Mutation Consortium initially presented data at the American Society of Clinical Oncology 2011 annual meeting and for the first approximately 800 patients tested, reported mutation frequencies of 25 percent
         <em>
          KRAS
         </em>
         ; 23 percent
         <em>
          EGFR
         </em>
         ; 6 percent
         <em>
          ALK
         </em>
         rearrangements; and 3 percent or less each of
         <em>
          BRAF
         </em>
         , phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (
         <em>
          PIK3CA
         </em>
         ), mesenchymal-epithelial transition factor (
         <em>
          MET
         </em>
         ) amplification, human epidermal growth factor receptor 2 (
         <em>
          HER2
         </em>
         ),
         <em>
         </em>
         MAP/ERK kinase 1 (
         <em>
          MEK1
         </em>
         ), and neuroblastoma RAS viral oncogene homolog (
         <em>
          NRAS
         </em>
         ) [
         <a href="#rid170">
          170
         </a>
         ]. Though those results are for adenocarcinomas in general, the identification of such mutations in over 60 percent of patients sampled and the mutually exclusive nature of the majority of those mutations indicate how far we have come in our biologic understanding of adenocarcinoma, the most frequent histology in never smokers.
        </p>
        <p>
         Further updates have confirmed these relative percentages of mutations, which have also been looked at by The Cancer Genome Atlas effort [
         <a href="#rid171">
          171
         </a>
         ]. Additional mutations, such as
         <em>
          ROS1
         </em>
         and
         <em>
          RET
         </em>
         , are frequently more common in never smokers and have been identified at a rapid pace [
         <a href="#rid172">
          172,173
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16538.html" rel="external">
          "Personalized, genotype-directed therapy for advanced non-small cell lung cancer", section on 'ROS1 rearrangements'
         </a>
         .)
        </p>
        <p>
         An analysis of 229 tumors from never smokers in Korea identified
         <em>
          EGFR
         </em>
         mutations,
         <em>
          ALK
         </em>
         gene rearrangements, and
         <em>
          KRAS
         </em>
         mutations in 48, 8, and 4 percent of cases, respectively [
         <a href="#rid174">
          174
         </a>
         ]. A surgical series of 349 never smoker women with lung adenocarcinoma in China identified known driver mutations in nearly 90 percent; these were predominantly
         <em>
          EGFR
         </em>
         (76 percent) mutations, with less than 5 percent each of
         <em>
          HER2
         </em>
         ,
         <em>
          EML4-ALK
         </em>
         ,
         <em>
          KRAS
         </em>
         , and
         <em>
          BRAF
         </em>
         [
         <a href="#rid175">
          175
         </a>
         ]. A smaller study in an area of China known for high rates of lung cancer in never smokers potentially related to coal use, found very high rates of an otherwise less common
         <em>
          EGFR
         </em>
         mutation, G719X, and a 15 percent rate of
         <em>
          KRAS
         </em>
         mutations in never smokers with lung cancer [
         <a href="#rid176">
          176
         </a>
         ]. An analysis in the United States of over 800 patients with advanced-stage NSCLC, of whom one-third were never smokers, found only a 4 percent rate of
         <em>
          KRAS
         </em>
         mutations but a 49 percent rate of
         <em>
          EGFR
         </em>
         mutations in lung cancers from never smokers compared with 15 percent
         <em>
          KRAS
         </em>
         and approximately 30 percent
         <em>
          EGFR
         </em>
         mutations in those with up to 15 pack-years of smoking history and 40 percent
         <em>
          KRAS
         </em>
         and only 11 percent
         <em>
          EGFR
         </em>
         mutations in those with at least a 15 pack-year smoking history [
         <a href="#rid177">
          177
         </a>
         ]. This provides further support to the assertion that targetable oncogenic mutant kinases can now be identified in the majority of lung adenocarcinomas from never smokers, especially in East Asian patients.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          PROGNOSIS AND TREATMENT IMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Whether or not patients with non-small cell lung cancer (NSCLC) who are never smokers have a better response to standard treatment and/or a better prognosis than those with a positive smoking history is uncertain. Some observational studies have demonstrated a better outcome [
         <a href="#rid28">
          28,178-181
         </a>
         ], although this has not been true in all studies [
         <a href="#rid182">
          182-184
         </a>
         ].
        </p>
        <p>
         As an example, in an analysis of 12,000 patients from California, smokers had a shorter survival compared with never smokers (hazard ratio [HR] for death 1.09, 95% CI 1.00-1.18) [
         <a href="#rid28">
          28
         </a>
         ]. Similarly, in another study of patients with lung adenocarcinoma comparing 132 never smokers with 522 current smokers, it was found that the five-year survival was significantly better among never smokers (23 versus 16 percent), a difference that was significant on multivariate analysis [
         <a href="#rid178">
          178
         </a>
         ]. By contrast, in another study of 254 patients with lung cancer, the five-year survival was not significantly different in never smokers compared with smokers (27 versus 31 percent, respectively) [
         <a href="#rid182">
          182
         </a>
         ]. Subsequently, a much larger lung cancer registry trial, which included over 15,000 Japanese and over 13,000 White American patients from Southern California, demonstrated a statistically significant improvement in survival for the patients with no smoking history [
         <a href="#rid29">
          29
         </a>
         ]. In an expanded analysis of 26,957 NSCLC patients from Japan, the median overall survival was significantly longer for never smokers compared with ever smokers (30 versus 19 months) [
         <a href="#rid185">
          185
         </a>
         ].
        </p>
        <p>
         Other studies suggest that the cancers that develop in nonsmokers are more likely than those in smokers to harbor actionable driver mutations. In a detailed prospective molecular epidemiology study conducted in Japan in over 950 patients, half of whom were never smokers, epidermal growth factor receptor (
         <em>
          EGFR
         </em>
         ) mutations were found in over 65 percent of the never smokers compared with &lt;25 percent of the ever smokers; anaplastic lymphoma kinase (
         <em>
          ALK
         </em>
         ) translocations were twice as likely in the never smoker population (5.1 percent) compared with the ever smoker cohort (2.7 percent). Tumor protein p53 (
         <em>
          TP53
         </em>
         ) and Kirsten rat sarcoma viral oncogene homolog (
         <em>
          KRAS
         </em>
         ) mutations, however, were much more common in the ever smoker group [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
         A meta-analysis of 167 epidemiologic studies including over 63,000 lung cancer cases evaluated the frequency of specific driver mutations by smoking status. Lung cancer patients who were never smokers had increased odds of
         <em>
          EGFR
         </em>
         mutations compared with ever smokers, though this association was less apparent for Asian never smokers compared with other groups (odds ratio [OR] 3.89 versus 6.29) [
         <a href="#rid186">
          186
         </a>
         ]. Similar group differences were seen for
         <em>
          ALK
         </em>
         translocations (OR 2.21 in Asian never smokers versus OR 4.09 in other groups).
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          EGFR inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinically important differences in treatment response are seen with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (
         <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">
          erlotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">
          gefitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">
          afatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">
          osimertinib
         </a>
         ). Higher response rates and better survival have been reported in never smokers with these drugs compared with current or former smokers, though the true factor is presence or absence of an
         <em>
          EGFR
         </em>
         -activating mutation [
         <a href="#rid143">
          143,187,188
         </a>
         ].
        </p>
        <p>
         The iPASS and First-Signal trials comparing first-line
         <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">
          gefitinib
         </a>
         versus chemotherapy for never smoking Asian patients with advanced-stage NSCLC emphasize this point [
         <a href="#rid189">
          189,190
         </a>
         ]. In both studies, high frequencies of
         <em>
          EGFR
         </em>
         mutations were found among never smokers, and gefitinib conferred an overall progression-free survival benefit only in those with activating
         <em>
          EGFR
         </em>
         mutations, while those without the
         <em>
          EGFR
         </em>
         -activating mutations did better with first-line chemotherapy. Thus, smoking status should not be used as a determining factor in selection of therapy, though the pretest probability of an actionable driver mutation is higher in those who develop lung cancer as a never smoker, and testing for these mutations is critical in that patient population. (See
         <a class="medical medical_review" href="/z/d/html/4630.html" rel="external">
          "Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H509181417">
         <span class="h2">
          Checkpoint inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many developments in lung cancer have been in the use of immune checkpoint inhibitors. The activity of the checkpoint inhibitors can be predicted to some extent by programmed death-ligand 1 (PD-L1) expression levels, but other factors play a key role as well. One of the earliest clinical observations was that responses were more likely in patients who developed lung cancer who had a smoking history compared with never smokers. However, in one meta-analysis of five studies of second-line checkpoint inhibitor therapy versus chemotherapy, the never-smoker patient cohorts had similar survival benefits compared with the current/former smokers (HR 0.73, 95% CI 0.62-0.87 for never smokers versus HR 0.69, 95% CI 0.61-0.78 for current/former smoker groups) [
         <a href="#rid191">
          191
         </a>
         ].
        </p>
        <p>
         In a specific analysis of patients with
         <em>
          KRAS
         </em>
         -mutated NSCLC, investigators found that patients with a smoking history were more likely to express PD-L1 (44 percent) versus former (20 percent) or never smokers (13 percent). Though PD-L1 expression is not the only marker of programmed cell death protein 1 checkpoint inhibitor efficacy, this does add to the data supporting mechanisms of resistance to checkpoint inhibitor therapy in those who are never smokers [
         <a href="#rid192">
          192
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2434473965">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112231.html" rel="external">
          "Society guideline links: Diagnosis and management of lung cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incidence
         </strong>
         – Although most cases of lung cancer are due to tobacco smoking, lung cancer among never smokers is an important problem, with the age-adjusted incidence rate for lung cancer in never smokers aged 40 to 79 years ranging from 11.2 to 13.7 per 100,000 person-years for men and from 15.2 to 20.8 per 100,000 person-years for women. (See
         <a class="local">
          'Incidence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Although the etiology for lung cancer among never smokers is not always clear, risk factors include air pollution, secondhand tobacco smoke, radon, and other environmental exposures. (See
         <a class="local">
          'Risk factors'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4640.html" rel="external">
          "Cigarette smoking and other possible risk factors for lung cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathology
         </strong>
         – Adenocarcinoma is the most common pathology among never smokers and is more common than among ever smokers. (See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Molecular biology
         </strong>
         – There are important differences at the molecular level between lung cancers arising in people who have never smoked and those who currently smoke or previously smoked. The best understood of these are the abnormalities in the epidermal growth factor receptor (EGFR) pathway. These EGFR pathway abnormalities seen in never smokers have been associated with a particular responsiveness to
         <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">
          erlotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">
          gefitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">
          afatinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">
          osimertinib
         </a>
         and other agents that inhibit EGFR tyrosine kinase. The anaplastic lymphoma kinase (
         <em>
          ALK
         </em>
         ) fusion oncogene is another molecular variant in non-small cell lung cancer that is seen more frequently in never smokers and for which targeted therapy is now available. Similar increases in frequency of other driver mutations are reported in lung cancer in never smokers. (See
         <a class="local">
          'Molecular biology'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71:209.
          </a>
         </li>
         <li class="breakAll">
          Brambilla E, Travis WD. Lung cancer. In: World Cancer Report, Stewart BW, Wild CP (Eds), World Health Organization, Lyon 2014.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Islami F, Ward EM, Sung H, et al. Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics. J Natl Cancer Inst 2021; 113:1648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giovino GA. Epidemiology of tobacco use in the United States. Oncogene 2002; 21:7326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers--a different disease. Nat Rev Cancer 2007; 7:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007; 25:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yano T, Miura N, Takenaka T, et al. Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival. Cancer 2008; 113:1012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subramanian J, Govindan R. Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol 2008; 9:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subramanian J, Govindan R. Lung cancer in 'Never-smokers': a unique entity. Oncology (Williston Park) 2010; 24:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudin CM, Avila-Tang E, Harris CC, et al. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res 2009; 15:5646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurahara Y, Kawaguchi T, Tachibana K, et al. Small-cell lung cancer in never-smokers: a case series with information on family history of cancer and environmental tobacco smoke. Clin Lung Cancer 2012; 13:75.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Lung cancer among people who never smoked. https://www.cdc.gov/cancer/lung/nonsmokers/index.htm#:~:text=About%2050%25%20to%2060%25%20of%20lung%20cancers%20found,flat%20cells%20lining%20the%20inside%20of%20the%20lungs%29. (Accessed on January 11, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008; 100:1672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol 2007; 25:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bain C, Feskanich D, Speizer FE, et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 2004; 96:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. J Womens Health 1997; 6:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein L, Allen M, Anton-Culver H, et al. High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control 2002; 13:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 2000; 151:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haiman CA, Stram DO, Wilkens LR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006; 354:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yong LC, Brown CC, Schatzkin A, et al. Intake of vitamins E, C, and A and risk of lung cancer. The NHANES I epidemiologic followup study. First National Health and Nutrition Examination Survey. Am J Epidemiol 1997; 146:231.
          </a>
         </li>
         <li class="breakAll">
          Surveillance, Epidemiology, and End Results (SEER) Program. Seer*Stat Database: Incidence - SEER 13 Regs Public-Use, Nov 2004 Sub for Expanded Races (1992-2002). www.seer.cancer.gov (Accessed on May 12, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ou SH, Ziogas A, Zell JA. Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): High percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity. J Clin Oncol 2008; 26S: ASCO #8004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ou SH, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009; 4:1083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thun MJ, Hannan LM, Adams-Campbell LL, et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med 2008; 5:e185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boffetta P, Järvholm B, Brennan P, Nyrén O. Incidence of lung cancer in a large cohort of non-smoking men from Sweden. Int J Cancer 2001; 94:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thun MJ, Henley SJ, Burns D, et al. Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst 2006; 98:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zell JA, Ou SH, Ziogas A, Anton-Culver H. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol 2005; 23:8396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawaguchi T, Matsumura A, Fukai S, et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol 2010; 5:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cufari ME, Proli C, De Sousa P, et al. Increasing frequency of non-smoking lung cancer: Presentation of patients with early disease to a tertiary institution in the UK. Eur J Cancer 2017; 84:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pelosof L, Ahn C, Gao A, et al. Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions. J Natl Cancer Inst 2017; 109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toh CK, Ong WS, Lim WT, et al. A Decade of Never-smokers Among Lung Cancer Patients-Increasing Trend and Improved Survival. Clin Lung Cancer 2018; 19:e539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nyberg F, Agudo A, Boffetta P, et al. A European validation study of smoking and environmental tobacco smoke exposure in nonsmoking lung cancer cases and controls. Cancer Causes Control 1998; 9:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wells AJ, English PB, Posner SF, et al. Misclassification rates for current smokers misclassified as nonsmokers. Am J Public Health 1998; 88:1503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tseng CH, Tsuang BJ, Chiang CJ, et al. The Relationship Between Air Pollution and Lung Cancer in Nonsmokers in Taiwan. J Thorac Oncol 2019; 14:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brenner DR, Hung RJ, Tsao MS, et al. Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors. BMC Cancer 2010; 10:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donington JS, Le QT, Wakelee HA. Lung cancer in women: exploring sex differences in susceptibility, biology, and therapeutic response. Clin Lung Cancer 2006; 8:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakai K, Ando M, Ozasa K, et al. Updated information on risk factors for lung cancer: findings from the JACC Study. J Epidemiol 2005; 15 Suppl 2:S134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawaguchi T, Takada M, Kubo A, et al. Gender, histology, and time of diagnosis are important factors for prognosis: analysis of 1499 never-smokers with advanced non-small cell lung cancer in Japan. J Thorac Oncol 2010; 5:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gomez SL, Chang ET, Shema SJ, et al. Survival following non-small cell lung cancer among Asian/Pacific Islander, Latina, and Non-Hispanic white women who have never smoked. Cancer Epidemiol Biomarkers Prev 2011; 20:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu NS, Spitz MR, Kemp BL, et al. Adenocarcinoma of the lung in young patients: the M. D. Anderson experience. Cancer 2000; 88:1837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toh CK, Gao F, Lim WT, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006; 24:2245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brennan P, Buffler PA, Reynolds P, et al. Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers: a pooled analysis of two large studies. Int J Cancer 2004; 109:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorlova OY, Zhang Y, Schabath MB, et al. Never smokers and lung cancer risk: a case-control study of epidemiological factors. Int J Cancer 2006; 118:1798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vineis P, Airoldi L, Veglia F, et al. Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ 2005; 330:277.
          </a>
         </li>
         <li class="breakAll">
          Wu A. Carcinogenic effects. In: Health Effects of Exposure to Environmental Tobacco Smoke, Shopland DR, Zeise L, Dunn A (Eds), National Cancer Institute, Bethesda, MD 1999.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vineis P, Alavanja M, Buffler P, et al. Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 2004; 96:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 2004; 83:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vineis P, Hoek G, Krzyzanowski M, et al. Lung cancers attributable to environmental tobacco smoke and air pollution in non-smokers in different European countries: a prospective study. Environ Health 2007; 6:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clément-Duchêne C, Vignaud JM, Stoufflet A, et al. Characteristics of never smoker lung cancer including environmental and occupational risk factors. Lung Cancer 2010; 67:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asomaning K, Miller DP, Liu G, et al. Second hand smoke, age of exposure and lung cancer risk. Lung Cancer 2008; 61:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurahashi N, Inoue M, Liu Y, et al. Passive smoking and lung cancer in Japanese non-smoking women: a prospective study. Int J Cancer 2008; 122:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olivo-Marston SE, Yang P, Mechanic LE, et al. Childhood exposure to secondhand smoke and functional mannose binding lectin polymorphisms are associated with increased lung cancer risk. Cancer Epidemiol Biomarkers Prev 2009; 18:3375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor R, Najafi F, Dobson A. Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. Int J Epidemiol 2007; 36:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veglia F, Vineis P, Overvad K, et al. Occupational exposures, environmental tobacco smoke, and lung cancer. Epidemiology 2007; 18:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang A, Kubo J, Luo J, et al. Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort. Ann Oncol 2015; 26:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krishnan VG, Ebert PJ, Ting JC, et al. Whole-genome sequencing of asian lung cancers: second-hand smoke unlikely to be responsible for higher incidence of lung cancer among Asian never-smokers. Cancer Res 2014; 74:6071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leuraud K, Schnelzer M, Tomasek L, et al. Radon, smoking and lung cancer risk: results of a joint analysis of three European case-control studies among uranium miners. Radiat Res 2011; 176:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samet JM. Radon and lung cancer. J Natl Cancer Inst 1989; 81:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krewski D, Lubin JH, Zielinski JM, et al. A combined analysis of North American case-control studies of residential radon and lung cancer. J Toxicol Environ Health A 2006; 69:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darby S, Hill D, Auvinen A, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ 2005; 330:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandler DP, Weinberg CR, Shore DL, et al. Indoor radon and lung cancer risk in connecticut and utah. J Toxicol Environ Health A 2006; 69:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol 2005; 23:3175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottschall EB. Occupational and environmental thoracic malignancies. J Thorac Imaging 2002; 17:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neuberger JS, Field RW. Occupation and lung cancer in nonsmokers. Rev Environ Health 2003; 18:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Loon AJ, Kant IJ, Swaen GM, et al. Occupational exposure to carcinogens and risk of lung cancer: results from The Netherlands cohort study. Occup Environ Med 1997; 54:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters S, Kromhout H, Olsson AC, et al. Occupational exposure to organic dust increases lung cancer risk in the general population. Thorax 2012; 67:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guha N, Merletti F, Steenland NK, et al. Lung cancer risk in painters: a meta-analysis. Environ Health Perspect 2010; 118:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen CL, Hsu LI, Chiou HY, et al. Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan. JAMA 2004; 292:2984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferreccio C, González C, Milosavjlevic V, et al. Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology 2000; 11:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feskanich D, Ziegler RG, Michaud DS, et al. Prospective study of fruit and vegetable consumption and risk of lung cancer among men and women. J Natl Cancer Inst 2000; 92:1812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galeone C, Negri E, Pelucchi C, et al. Dietary intake of fruit and vegetable and lung cancer risk: a case-control study in Harbin, northeast China. Ann Oncol 2007; 18:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam TK, Cross AJ, Consonni D, et al. Intakes of red meat, processed meat, and meat mutagens increase lung cancer risk. Cancer Res 2009; 69:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim WY, Chuah KL, Eng P, et al. Meat consumption and risk of lung cancer among never-smoking women. Nutr Cancer 2011; 63:850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorlova OY, Weng SF, Hernandez L, et al. Dietary patterns affect lung cancer risk in never smokers. Nutr Cancer 2011; 63:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fehringer G, Brenner DR, Zhang ZF, et al. Alcohol and lung cancer risk among never smokers: A pooled analysis from the international lung cancer consortium and the SYNERGY study. Int J Cancer 2017; 140:1976.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boffetta P, Nyberg F. Contribution of environmental factors to cancer risk. Br Med Bull 2003; 68:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu IT, Chiu YL, Au JS, et al. Dose-response relationship between cooking fumes exposures and lung cancer among Chinese nonsmoking women. Cancer Res 2006; 66:4961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ko YC, Cheng LS, Lee CH, et al. Chinese food cooking and lung cancer in women nonsmokers. Am J Epidemiol 2000; 151:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleinerman RA, Wang Z, Wang L, et al. Lung cancer and indoor exposure to coal and biomass in rural China. J Occup Environ Med 2002; 44:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gao YT, Blot WJ, Zheng W, et al. Lung cancer among Chinese women. Int J Cancer 1987; 40:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang TJ, Zhou BS, Shi JP. Lung cancer in nonsmoking Chinese women: a case-control study. Lung Cancer 1996; 14 Suppl 1:S93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen XB, Wang GX, Huang YZ, et al. Analysis and estimates of attributable risk factors for lung cancer in Nanjing, China. Lung Cancer 1996; 14 Suppl 1:S107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner MC, Krewski D, Pope CA 3rd, et al. Long-term ambient fine particulate matter air pollution and lung cancer in a large cohort of never-smokers. Am J Respir Crit Care Med 2011; 184:1374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamra GB, Guha N, Cohen A, et al. Outdoor particulate matter exposure and lung cancer: a systematic review and meta-analysis. Environ Health Perspect 2014; 122:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swanton C, Hill W, Lim E, et al. LBA1 Mechanism of action and an actionable inflammatory axis for air pollution induced non-small cell lung cancer: Towards molecular cancer prevention. Ann Oncol 2022; 33S:ESMO #S1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Littman AJ, Thornquist MD, White E, et al. Prior lung disease and risk of lung cancer in a large prospective study. Cancer Causes Control 2004; 15:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayne ST, Buenconsejo J, Janerich DT. Previous lung disease and risk of lung cancer among men and women nonsmokers. Am J Epidemiol 1999; 149:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu AH, Fontham ET, Reynolds P, et al. Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1995; 141:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000; 161:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wells C, Mannino DM. Pulmonary fibrosis and lung cancer in the United States: analysis of the multiple cause of death mortality data, 1979 through 1991. South Med J 1996; 89:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciotti M, Giuliani L, Ambrogi V, et al. Detection and expression of human papillomavirus oncogenes in non-small cell lung cancer. Oncol Rep 2006; 16:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen YC, Chen JH, Richard K, et al. Lung adenocarcinoma and human papillomavirus infection. Cancer 2004; 101:1428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng YW, Chiou HL, Sheu GT, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001; 61:2799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bohlmeyer T, Le TN, Shroyer AL, et al. Detection of human papillomavirus in squamous cell carcinomas of the lung by polymerase chain reaction. Am J Respir Cell Mol Biol 1998; 18:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasegawa Y, Ando M, Kubo A, et al. Human papilloma virus in non-small cell lung cancer in never smokers: a systematic review of the literature. Lung Cancer 2014; 83:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anantharaman D, Gheit T, Waterboer T, et al. No causal association identified for human papillomavirus infections in lung cancer. Cancer Res 2014; 74:3525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawaguchi T, Koh Y, Ando M, et al. Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study. J Clin Oncol 2016; 34:2247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu AH, Fontham ET, Reynolds P, et al. Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1996; 143:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brownson RC, Alavanja MC, Caporaso N, et al. Family history of cancer and risk of lung cancer in lifetime non-smokers and long-term ex-smokers. Int J Epidemiol 1997; 26:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu PF, Lee CH, Wang MJ, et al. Cancer aggregation and complex segregation analysis of families with female non-smoking lung cancer probands in Taiwan. Eur J Cancer 2004; 40:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz AG, Yang P, Swanson GM. Familial risk of lung cancer among nonsmokers and their relatives. Am J Epidemiol 1996; 144:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorlova OY, Weng SF, Zhang Y, et al. Aggregation of cancer among relatives of never-smoking lung cancer patients. Int J Cancer 2007; 121:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gao Y, Goldstein AM, Consonni D, et al. Family history of cancer and nonmalignant lung diseases as risk factors for lung cancer. Int J Cancer 2009; 125:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tse LA, Yu IT, Rothman N, et al. Joint effects of environmental exposures and familial susceptibility to lung cancer in Chinese never smoking men and women. J Thorac Oncol 2014; 9:1066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorlova OY, Weng SF, Zhang Y, et al. DNA repair capacity and lung cancer risk in never smokers. Cancer Epidemiol Biomarkers Prev 2008; 17:1322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amos CI, Pinney SM, Li Y, et al. A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers. Cancer Res 2010; 70:2359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Broderick P, Webb E, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008; 40:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Broderick P, Matakidou A, et al. Role of 5p15.33 (TERT-CLPTM1L), 6p21.33 and 15q25.1 (CHRNA5-CHRNA3) variation and lung cancer risk in never-smokers. Carcinogenesis 2010; 31:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsiung CA, Lan Q, Hong YC, et al. The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet 2010; 6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Y, Sheu CC, Ye Y, et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 2010; 11:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Truong T, Hung RJ, Amos CI, et al. Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst 2010; 102:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahn MJ, Won HH, Lee J, et al. The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations. Hum Genet 2012; 131:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang P, Li Y, Jiang R, et al. A rigorous and comprehensive validation: common genetic variations and lung cancer. Cancer Epidemiol Biomarkers Prev 2010; 19:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lan Q, Hsiung CA, Matsuo K, et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet 2012; 44:1330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu X, Wang L, Ye Y, et al. Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers. Cancer Res 2013; 73:4028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang HG, Lee SY, Jeon HS, et al. A functional polymorphism in CSF1R gene is a novel susceptibility marker for lung cancer among never-smoking females. J Thorac Oncol 2014; 9:1647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005; 37:1315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikeda K, Nomori H, Mori T, et al. Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg 2008; 85:1430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohtsuka K, Ohnishi H, Kurai D, et al. Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation. J Clin Oncol 2011; 29:e191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Noesel J, van der Ven WH, van Os TA, et al. Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation. J Clin Oncol 2013; 31:e161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto H, Higasa K, Sakaguchi M, et al. Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Cancer Inst 2014; 106:djt338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stabile LP, Davis AL, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 2002; 62:2141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mollerup S, Jørgensen K, Berge G, Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 2002; 37:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu CT, Chang YL, Shih JY, Lee YC. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 2005; 130:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 1994; 86:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz AG, Wenzlaff AS, Prysak GM, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol 2007; 25:5785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh SW, Myung SK, Park JY, et al. Hormone therapy and risk of lung cancer: a meta-analysis. J Womens Health (Larchmt) 2010; 19:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabat GC, Miller AB, Rohan TE. Reproductive and hormonal factors and risk of lung cancer in women: a prospective cohort study. Int J Cancer 2007; 120:2214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paulus JK, Asomaning K, Kraft P, et al. Parity and risk of lung cancer in women. Am J Epidemiol 2010; 171:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel JD, Gray RG, Stewart JA, et al. Tamoxifen does not reduce the risk of lung cancer in women. J Clin Oncol 2005; 23S: ASCO #7212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009; 374:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chlebowski RT, Anderson GL, Manson JE, et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst 2010; 102:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chlebowski RT, Wakelee HA, Rohan TE, et al. Smoking and estrogen plus progestin (E+P) and lung cancer incidence and mortality. J Clin Oncol 2013; 31S: ASCO #1524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devarakonda S, Li Y, Martins Rodrigues F, et al. Genomic Profiling of Lung Adenocarcinoma in Never-Smokers. J Clin Oncol 2021; 39:3747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sonobe M, Manabe T, Wada H, Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 2005; 93:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64:8919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pham D, Kris MG, Riely GJ, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006; 24:1700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006; 12:1647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toyooka S, Matsuo K, Shigematsu H, et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res 2007; 13:5763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee YJ, Shim HS, Kang YA, et al. Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. J Cancer Res Clin Oncol 2010; 136:1937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dutu T, Michiels S, Fouret P, et al. Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. Ann Oncol 2005; 16:1906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee YJ, Cho BC, Jee SH, et al. Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. J Clin Oncol 2010; 28:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawaguchi T, Ando M, Kubo A, et al. Long exposure of environmental tobacco smoke associated with activating EGFR mutations in never-smokers with non-small cell lung cancer. Clin Cancer Res 2011; 17:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Calvez F, Mukeria A, Hunt JD, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 2005; 65:5076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008; 14:5731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27:4247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009; 15:5216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010; 9:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 2003; 21:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Planchard D, Domont J, Taranchon E, et al. The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. Ann Oncol 2009; 20:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mountzios G, Planchard D, Besse B, et al. Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers. Clin Cancer Res 2008; 14:4096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo YL, Hsiao CF, Jou YS, et al. ATM polymorphisms and risk of lung cancer among never smokers. Lung Cancer 2010; 69:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong MP, Fung LF, Wang E, et al. Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers. Cancer 2003; 97:1263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 2001; 61:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Divine KK, Pulling LC, Marron-Terada PG, et al. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. Int J Cancer 2005; 114:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tessema M, Yu YY, Stidley CA, et al. Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis 2009; 30:1132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seike M, Goto A, Okano T, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A 2009; 106:12085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dasgupta S, Soudry E, Mukhopadhyay N, et al. Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation. J Cell Physiol 2012; 227:2451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012; 150:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SC, Jung Y, Park J, et al. A high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokers. PLoS One 2013; 8:e55596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson BE, Kris MG, Berry LD, et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2013; 31S: ASCO #8019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013; 45:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med 2012; 18:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012; 18:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HR, Shim HS, Chung JH, et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 2012; 118:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Sun Y, Pan Y, et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 2012; 18:1947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hosgood HD 3rd, Pao W, Rothman N, et al. Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. Respir Med 2013; 107:1755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varghese AM, Sima CS, Chaft JE, et al. Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. J Thorac Oncol 2013; 8:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nordquist LT, Simon GR, Cantor A, et al. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004; 126:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sardari Nia P, Weyler J, Colpaert C, et al. Prognostic value of smoking status in operated non-small cell lung cancer. Lung Cancer 2005; 47:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest 2007; 132:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsao AS, Liu D, Lee JJ, et al. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 2006; 106:2428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subramanian J, Velcheti V, Gao F, Govindan R. Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC). J Thorac Oncol 2007; 2:827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meguid RA, Hooker CM, Harris J, et al. Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers. Chest 2010; 138:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010; 5:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman AM, Sun KY, Ruestow P, et al. Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. Lung Cancer 2016; 102:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012; 30:1122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang T, Liu H, Qiao M, et al. Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer. Clin Lung Cancer 2018; 19:e177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calles A, Liao X, Sholl LM, et al. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol 2015; 10:1726.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4600 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33538338" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33538338" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34240195" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12379876" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Epidemiology of tobacco use in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33433946" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Cancer Statistics, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17882278" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Lung cancer in never smokers--a different disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17290066" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Lung cancer in never smokers: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18618510" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18598932" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Molecular genetics of lung cancer in people who have never smoked.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20187318" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Lung cancer in 'Never-smokers': a unique entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19755392" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Lung cancer in never smokers: molecular profiles and therapeutic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21729654" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Small-cell lung cancer in never-smokers: a case series with information on family history of cancer and environmental tobacco smoke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21729654" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Small-cell lung cancer in never-smokers: a case series with information on family history of cancer and environmental tobacco smoke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19033571" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17290054" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Lung cancer incidence in never smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15173266" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Lung cancer rates in men and women with comparable histories of smoking.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9065374" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The Nurses' Health Study: 20-year contribution to the understanding of health among women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12296510" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10695593" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16436765" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Ethnic and racial differences in the smoking-related risk of lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9247007" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Intake of vitamins E, C, and A and risk of lung cancer. The NHANES I epidemiologic followup study. First National Health and Nutrition Examination Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9247007" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Intake of vitamins E, C, and A and risk of lung cancer. The NHANES I epidemiologic followup study. First National Health and Nutrition Examination Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): High percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19652625" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18788891" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11745449" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Incidence of lung cancer in a large cohort of non-smoking men from Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16705123" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Lung cancer death rates in lifelong nonsmokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16293870" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20526205" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10926586" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28783541" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Increasing frequency of non-smoking lung cancer: Presentation of patients with early disease to a tertiary institution in the UK.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28132018" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29627315" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A Decade of Never-smokers Among Lung Cancer Patients-Increasing Trend and Improved Survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9578294" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A European validation study of smoking and environmental tobacco smoke exposure in nonsmoking lung cancer cases and controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9772852" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Misclassification rates for current smokers misclassified as nonsmokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30664991" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The Relationship Between Air Pollution and Lung Cancer in Nonsmokers in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15761078" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Global cancer statistics, 2002.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20546590" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16870042" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Lung cancer in women: exploring sex differences in susceptibility, biology, and therapeutic response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16127225" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Updated information on risk factors for lung cancer: findings from the JACC Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20502360" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Gender, histology, and time of diagnosis are important factors for prognosis: analysis of 1499 never-smokers with advanced non-small cell lung cancer in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21239685" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Survival following non-small cell lung cancer among Asian/Pacific Islander, Latina, and Non-Hispanic white women who have never smoked.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10760760" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Adenocarcinoma of the lung in young patients: the M. D. Anderson experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16710022" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14735478" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers: a pooled analysis of two large studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16217766" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Never smokers and lung cancer risk: a case-control study of epidemiological factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15681570" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15681570" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14734699" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Tobacco and cancer: recent epidemiological evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15285078" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Tobacco smoke and involuntary smoking.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17302981" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Lung cancers attributable to environmental tobacco smoke and air pollution in non-smokers in different European countries: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19464070" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Characteristics of never smoker lung cancer including environmental and occupational risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18191495" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Second hand smoke, age of exposure and lung cancer risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17935128" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Passive smoking and lung cancer in Japanese non-smoking women: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19959685" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Childhood exposure to secondhand smoke and functional mannose binding lectin polymorphisms are associated with increased lung cancer risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17690135" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18062064" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Occupational exposures, environmental tobacco smoke, and lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25316260" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25189529" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Whole-genome sequencing of asian lung cancers: second-hand smoke unlikely to be responsible for higher incidence of lung cancer among Asian never-smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21714633" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Radon, smoking and lung cancer risk: results of a joint analysis of three European case-control studies among uranium miners.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2654404" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Radon and lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16608828" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : A combined analysis of North American case-control studies of residential radon and lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15613366" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16608830" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Indoor radon and lung cancer risk in connecticut and utah.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15886304" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Epidemiology of lung cancer: looking to the future.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12082370" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Occupational and environmental thoracic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15025189" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Occupation and lung cancer in nonsmokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9538355" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Occupational exposure to carcinogens and risk of lung cancer: results from The Netherlands cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21856697" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Occupational exposure to organic dust increases lung cancer risk in the general population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20064777" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Lung cancer risk in painters: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15613666" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11055628" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Lung cancer and arsenic concentrations in drinking water in Chile.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11078758" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Prospective study of fruit and vegetable consumption and risk of lung cancer among men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17060488" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Dietary intake of fruit and vegetable and lung cancer risk: a case-control study in Harbin, northeast China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19141639" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Intakes of red meat, processed meat, and meat mutagens increase lung cancer risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21774592" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Meat consumption and risk of lung cancer among never-smoking women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21774612" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Dietary patterns affect lung cancer risk in never smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28120396" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Alcohol and lung cancer risk among never smokers: A pooled analysis from the international lung cancer consortium and the SYNERGY study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14757710" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Contribution of environmental factors to cancer risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16651454" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Dose-response relationship between cooking fumes exposures and lung cancer among Chinese nonsmoking women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10645816" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Chinese food cooking and lung cancer in women nonsmokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11977420" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Lung cancer and indoor exposure to coal and biomass in rural China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2824385" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Lung cancer among Chinese women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8785672" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Lung cancer in nonsmoking Chinese women: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8785656" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Analysis and estimates of attributable risk factors for lung cancer in Nanjing, China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21980033" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Long-term ambient fine particulate matter air pollution and lung cancer in a large cohort of never-smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24911630" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Outdoor particulate matter exposure and lung cancer: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : LBA1 Mechanism of action and an actionable inflammatory axis for air pollution induced non-small cell lung cancer: Towards molecular cancer prevention
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11830608" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15456995" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Prior lung disease and risk of lung cancer in a large prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9883789" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Previous lung disease and risk of lung cancer among men and women nonsmokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7771438" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10619790" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8638179" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Pulmonary fibrosis and lung cancer in the United States: analysis of the multiple cause of death mortality data, 1979 through 1991.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16786144" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Detection and expression of human papillomavirus oncogenes in non-small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15368331" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Lung adenocarcinoma and human papillomavirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11306446" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9476914" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Detection of human papillomavirus in squamous cell carcinomas of the lung by polymerase chain reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24252423" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Human papilloma virus in non-small cell lung cancer in never smokers: a systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24760422" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : No causal association identified for human papillomavirus infections in lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27161973" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8610670" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9169159" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Family history of cancer and risk of lung cancer in lifetime non-smokers and long-term ex-smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14728941" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Cancer aggregation and complex segregation analysis of families with female non-smoking lung cancer probands in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8797515" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Familial risk of lung cancer among nonsmokers and their relatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17304511" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Aggregation of cancer among relatives of never-smoking lung cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19350630" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Family history of cancer and nonmalignant lung diseases as risk factors for lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24852518" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Joint effects of environmental exposures and familial susceptibility to lung cancer in Chinese never smoking men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18559546" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : DNA repair capacity and lung cancer risk in never smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20215501" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18978787" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Common 5p15.33 and 6p21.33 variants influence lung cancer risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19955392" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Role of 5p15.33 (TERT-CLPTM1L), 6p21.33 and 15q25.1 (CHRNA5-CHRNA3) variation and lung cancer risk in never-smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20700438" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20304703" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Genetic variants and risk of lung cancer in never smokers: a genome-wide association study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20548021" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21866343" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20056643" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : A rigorous and comprehensive validation: common genetic variations and lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23143601" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23704207" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25144241" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : A functional polymorphism in CSF1R gene is a novel susceptibility marker for lung cancer among never-smoking females.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16258541" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18355544" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21172876" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23358982" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24317180" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8769313" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : ER beta: identification and characterization of a novel human estrogen receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11929836" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12140138" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Expression of estrogen receptors alpha and beta in human lung tissue and cell lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16214508" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8182770" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Re: Endocrine factors and adenocarcinoma of the lung in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12117397" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18089876" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20095904" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Hormone therapy and risk of lung cancer: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17278095" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Reproductive and hormonal factors and risk of lung cancer in women: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20123687" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Parity and risk of lung cancer in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Tamoxifen does not reduce the risk of lung cancer in women
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19767090" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20709992" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Smoking and estrogen plus progestin (E+P) and lung cancer incidence and mortality
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34591593" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Genomic Profiling of Lung Adenocarcinoma in Never-Smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16052218" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15604253" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16014883" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Erlotinib in lung cancer - molecular and clinical predictors of outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15329413" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16505411" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16533793" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17908966" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20237940" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16219624" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20008630" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21059816" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Long exposure of environmental tobacco smoke associated with activating EGFR mutations in never-smokers with non-small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15958551" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18794081" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19667264" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19671850" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20979469" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20624322" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12619108" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : The TP53 gene, tobacco exposure, and lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19297315" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18593986" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20004998" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : ATM polymorphisms and risk of lung cancer among never smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12599234" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11245426" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15578700" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19435948" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19597153" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21830212" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22980976" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Genomic landscape of non-small cell lung cancer in smokers and never-smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23405175" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : A high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24071849" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : The Cancer Genome Atlas Pan-Cancer analysis project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22395697" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Chipping away at the lung cancer genome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22327623" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : RET, ROS1 and ALK fusions in lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21720997" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22317764" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24055406" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23242442" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15302716" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15713518" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Prognostic value of smoking status in operated non-small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17573517" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16634096" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17805060" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16043829" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20507946" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20354456" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27987580" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16257339" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16014882" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Erlotinib in previously treated non-small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19692680" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22370314" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29175386" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26473645" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
